Spyre Therapeutics, Inc.
SYRENASDAQHealthcare● Active
$71.54
$-2.11(-2.87%)
Market Cap$4.3B
P/E Ratio—
52W High$78.8
52W Low$13.93
Spyre Therapeutics, Inc. (SYRE) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
SYRE · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 5, 2026EPS Actual
-$0.74
Est. -$0.66 · -12.1%
Revenue
—
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 5, 2026
After Market Close
▼ Miss EPS
SYRE reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Rev. $0.58B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
Rev. Est.$0.58B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 4, 2026 | -$0.73 | — | — | — | — | — |
| ▼ Q2 FY2026 | May 5, 2026 | -$0.66 | -$0.74 | -12.1% | — | — | — |
| ▼ Q1 FY2026 | Feb 19, 2026 | -$0.66 | -$0.70 | -6.1% | $0.09B | $0.14B | -36.6% |
| ▲ Q4 FY2025 | Nov 4, 2025 | -$0.68 | -$0.15 | +77.9% | — | — | — |
| ▲ Q3 FY2025 | Aug 5, 2025 | -$0.73 | -$0.49 | +32.9% | — | — | — |
| ▲ Q2 FY2025 | May 8, 2025 | -$0.76 | -$0.74 | +2.6% | — | — | — |
| ▲ Q1 FY2025 | Feb 27, 2025 | -$0.89 | -$0.81 | +9.0% | — | $0.00B | — |
| ▼ Q4 FY2024 | Nov 7, 2024 | -$0.80 | -$1.36 | -70.0% | — | $0.00B | — |
Q3 FY2026
Aug 4, 2026
EPS Actual
—
EPS Est.
-$0.73
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 5, 2026Miss
EPS Actual
-$0.74
EPS Est.
-$0.66
EPS Surpr.
-12.1%
Revenue
—
Q1 FY2026
Feb 19, 2026Miss
EPS Actual
-$0.70
EPS Est.
-$0.66
EPS Surpr.
-6.1%
Revenue
$0.09B
Q4 FY2025
Nov 4, 2025Beat
EPS Actual
-$0.15
EPS Est.
-$0.68
EPS Surpr.
+77.9%
Revenue
—
Q3 FY2025
Aug 5, 2025Beat
EPS Actual
-$0.49
EPS Est.
-$0.73
EPS Surpr.
+32.9%
Revenue
—
Q2 FY2025
May 8, 2025Beat
EPS Actual
-$0.74
EPS Est.
-$0.76
EPS Surpr.
+2.6%
Revenue
—
Q1 FY2025
Feb 27, 2025Beat
EPS Actual
-$0.81
EPS Est.
-$0.89
EPS Surpr.
+9.0%
Revenue
—
Q4 FY2024
Nov 7, 2024Miss
EPS Actual
-$1.36
EPS Est.
-$0.80
EPS Surpr.
-70.0%
Revenue
—
Analyst Estimates
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-0.86 | $-0.86 | $-0.86 | 3 |
| Q3 FY2027 | $-0.85 | $-0.85 | $-0.85 | 4 |
| Q2 FY2027 | $-0.82 | $-0.82 | $-0.82 | 3 |
| Q1 FY2027 | $-0.78 | $-0.78 | $-0.78 | 3 |
| Q4 FY2026 | $-0.69 | $-0.69 | $-0.69 | 7 |
| Q3 FY2026 | $-0.89 | $-0.71 | $-0.59 | 9 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 5, 2026 | -12.1% | $69.13 | $71.01 | +2.72% |
| ▼ Q1 FY2026 | Feb 19, 2026 | -6.1% | $36.60 | $37.81 | +3.31% |
| ▲ Q4 FY2025 | Nov 4, 2025 | +77.9% | $23.78 | $22.98 | -3.36% |
| ▲ Q3 FY2025 | Aug 5, 2025 | +32.9% | $16.16 | $16.87 | +4.39% |
| ▲ Q2 FY2025 | May 8, 2025 | +2.6% | $12.71 | $12.86 | +1.18% |
| ▲ Q1 FY2025 | Feb 27, 2025 | +9.0% | $19.00 | $18.37 | -3.32% |
| ▼ Q4 FY2024 | Nov 7, 2024 | -70.0% | $37.48 | $37.69 | +0.56% |
| ▲ Q3 FY2024 | Aug 7, 2024 | +4.4% | $26.04 | $24.55 | -5.72% |
Q2 FY2026+2.72%
Report Date
May 5, 2026
EPS Beat/Miss
-12.1%
Price Before
$69.13
Price After
$71.01
Q1 FY2026+3.31%
Report Date
Feb 19, 2026
EPS Beat/Miss
-6.1%
Price Before
$36.60
Price After
$37.81
Q4 FY2025-3.36%
Report Date
Nov 4, 2025
EPS Beat/Miss
+77.9%
Price Before
$23.78
Price After
$22.98
Q3 FY2025+4.39%
Report Date
Aug 5, 2025
EPS Beat/Miss
+32.9%
Price Before
$16.16
Price After
$16.87
Q2 FY2025+1.18%
Report Date
May 8, 2025
EPS Beat/Miss
+2.6%
Price Before
$12.71
Price After
$12.86
Q1 FY2025-3.32%
Report Date
Feb 27, 2025
EPS Beat/Miss
+9.0%
Price Before
$19.00
Price After
$18.37
Q4 FY2024+0.56%
Report Date
Nov 7, 2024
EPS Beat/Miss
-70.0%
Price Before
$37.48
Price After
$37.69
Q3 FY2024-5.72%
Report Date
Aug 7, 2024
EPS Beat/Miss
+4.4%
Price Before
$26.04
Price After
$24.55
Avg Beat Reaction-1.37%
Avg Miss Reaction+2.20%
Beat Rate5 / 8 quarters
Largest Move-5.72% (Q3 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: SYRE ends December
Spyre Therapeutics, Inc. (SYRE) most recently reported earnings on May 5, 2026 for Q2 FY2026, posting EPS of $-0.74 — missing the analyst consensus of $-0.66 by -12.1%. The next SYRE earnings date is expected around September 1, 2026.
Each quarter, investors track SYRE earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. SYRE revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
SYRE's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
SYRE earnings · 5 questionsSpyre Therapeutics, Inc.'s next earnings report is expected around September 1, 2026. SYRE typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; SYRE historically reports after market close (AMC).
SYRE earnings datewhen is SYRE earningsSYRE next earnings datewhen does SYRE report earningsSYRE earnings calendar
▸ Source: FMP · Spyre Therapeutics, Inc. SEC filings · US GAAP · Spyre Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026